Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are
Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal
Infections

A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic
Selection, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., May 27 /PRNewswire/ -- Arlington Medical
Resources (AMR) and Decision Resources find that surveyed physicians will
increase prescribing of Wyeth's Tygacil, Merck's Invanz and Johnson &
Johnson's Doribax in the next five years for the treatment of intra-abdominal
infections because of their potent broad-spectrum activity and efficacy
against gram-negative and anaerobic organisms.

"Treatment for intra-abdominal infections is largely empiric," stated Lisa
Arias, analyst at Decision Resources. "A variety of organisms, particularly
gram-negative aerobic bacteria and anaerobes, are documented in patients with
an intra-abdominal infection. In fact, the leading attribute that physicians
surveyed look for in a drug to treat intra-abdominal infections is its
activity against anaerobes."

The new report entitled Hospital Anti-Infectives Insight Series:
Intra-Abdominal Infections also finds that 96 percent of surveyed physicians
cite a drug's activity against anaerobes as the leading attribute in
antibiotic selection. Intra-abdominal infections are often polymicrobial in
nature and involve anaerobes specific to the etiology of the infection, so
activity against these organisms is advantageous even without bacterial
confirmation.

"Physicians also rank availability in intravenous formulation and a low
propensity to induce resistance as other important drug attributes that
influence their selection in antibiotics," added Ms. Arias. "While some agents
with anaerobic and gram negative activity, such as carbapenems, address some
of these attributes, no antibiotic captures all of the top most important
attributes which leaves opportunity for novel products to differentiate
themselves."

About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes
hospital antibiotic prescribing patterns using AMR's comprehensive and highly
detailed clinical data in conjunction with Decision Resources' disease area
knowledge, primary research and extensive understanding of emerging therapies
and forecasts. These reports examine the reasons behind physicians' product
preferences, factors driving hospital antibiotic prescribing patterns and
receptivity to emerging antibiotics.

Members of the media are welcome to attend our upcoming webinar entitled
Hospital Anti-Infectives Insight Series: Analyzing Prescribing Trends and
Emerging Therapies in the Hospital Antibiotic Market. The webinar will be held
on Wednesday, June 17, 2009 at 10 a.m. EDT. For more information, please
contact Gisselle Morales at 781.296.2691 or e-mail at gmorales@dresources.com.

About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the
pharmaceutical and diagnostic imaging industries. Research includes clinical
inpatient databases that directly link anti-infective drug with
indication/procedure, formulary and stocking status tracking studies, drug
purchasing audits and diagnostic imaging procedure volume/contrast media usage
audits. AMR is a Decision Resources, Inc. company.

About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Gisselle Morales Elizabeth Marshall
Decision Resources Decision Resources, Inc.
781-296-2691 781-296-2563
gmorales@dresources.com emarshall@dresources.com

SOURCE Decision Resources; Arlington Medical Resources

Gisselle Morales of Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com